Home/Pipeline/Orally Bioavailable KRASG12D Inhibitor

Orally Bioavailable KRASG12D Inhibitor

Solid Tumors

DiscoveryActive

Key Facts

Indication

Solid Tumors

Phase

Discovery

Status

Active

Company

Eilean Therapeutics

About Eilean Therapeutics

Eilean Therapeutics is a private, preclinical-stage biotech targeting treatment-resistant hematological cancers through a pipeline of novel small molecules. Its strategy centers on developing 'pan-variant' inhibitors that address multiple resistance mutations and escape pathways simultaneously, aiming to create more durable therapies. The company has a broad early pipeline targeting high-value oncogenic drivers like FLT3/IRAK4, BCL2, and Menin, with its most advanced program, a JAK2 V617F inhibitor, having entered first-in-human studies. Backed by experienced leadership and venture capital investors like OrbiMed, Eilean is positioned to tackle a significant unmet need in oncology.

View full company profile

Therapeutic Areas

Oncology Hematology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed